Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Catalyst Grant: Health Services and Economics Research in Cancer Control

McGill University

$26,186.00

Estimating the harms and benefits of cervical cancer screening in the pre- and post-HPV vaccination eras: a modelling study

EF 2016-17

Résumé
Cervical cancer screening is highly effective at preventing cervical cancer. However, screening leads to much overtreatment of lesions that would naturally regress and is associated with harms such as pain, anxiety, and future adverse pregnancy outcomes (low birth weight, premature birth). Canadian recommendations regarding cervical cancer screening seek to maximize preventive benefits while minimizing harms by recommending screening at 3-year intervals. However, it is very likely the balance of harms and benefits will shift in the near future due to more and more women being vaccinated against the human papillomavirus (HPV); screening will be less beneficial for these women due to their low risk of disease. Current screening guidelines will have to be changed in the next few years in order to manage HPV vaccinated women, but evidence is needed to predict how recommendations and newer technologies such as HPV DNA testing could impact health outcomes and the balance of harms/benefits. In this study, we will use a decision model to evaluate how the positive predictive value of a positive screening test and the net benefits of screening in terms of quality and quantity of life (quality-adjusted-life-years (QALY)) will change within the next few decades and in different age groups. QALY explicitly integrate individuals' health state preferences for different outcomes affected by screening. We will also model changes in adverse obstetric outcomes associated with screening, which have not been evaluated in previous decision models. The model will reproduce cervical cancer epidemiology and screening in Canada by using data from CANSIM and Canadian epidemiological studies to parameterize and calibrate the model. Results will help policy makers evaluate how the balance of harms and benefits of screening is likely to change over time, and decide whether different screening intervals or targeting different age groups would be most appropriate to minimize screening harms.
Programme
Catalyst Grant: Health Services and Economics Research in Cancer Control
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
359040
Name
Franco Eduardo L
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Health systems / services
Prcname2
Catalyst Grant: Health Services and Economics Research in Cancer Control
Projecttitle
Estimating the harms and benefits of cervical cancer screening in the pre- and post-HPV vaccination eras: a modelling study
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$26,186
Cihrequipment2
$0
Programname2
Catalyst Grant: Health Services and Economics Research in Cancer Control
Keyworddelim
Adverse Obstetric Outcomes; Cervical Cancer; Harms; Health Policy; Hpv Testing; Hpv Vaccination; Mathematical Modelling; Positive Predictive Value; Quality Adjusted Life-Years; Screening
Abstract
Cervical cancer screening is highly effective at preventing cervical cancer. However, screening leads to much overtreatment of lesions that would naturally regress and is associated with harms such as pain, anxiety, and future adverse pregnancy outcomes (low birth weight, premature birth). Canadian recommendations regarding cervical cancer screening seek to maximize preventive benefits while minimizing harms by recommending screening at 3-year intervals. However, it is very likely the balance of harms and benefits will shift in the near future due to more and more women being vaccinated against the human papillomavirus (HPV); screening will be less beneficial for these women due to their low risk of disease. Current screening guidelines will have to be changed in the next few years in order to manage HPV vaccinated women, but evidence is needed to predict how recommendations and newer technologies such as HPV DNA testing could impact health outcomes and the balance of harms/benefits. In this study, we will use a decision model to evaluate how the positive predictive value of a positive screening test and the net benefits of screening in terms of quality and quantity of life (quality-adjusted-life-years (QALY)) will change within the next few decades and in different age groups. QALY explicitly integrate individuals' health state preferences for different outcomes affected by screening. We will also model changes in adverse obstetric outcomes associated with screening, which have not been evaluated in previous decision models. The model will reproduce cervical cancer epidemiology and screening in Canada by using data from CANSIM and Canadian epidemiological studies to parameterize and calibrate the model. Results will help policy makers evaluate how the balance of harms and benefits of screening is likely to change over time, and decide whether different screening intervals or targeting different age groups would be most appropriate to minimize screening harms.
Competitiondate
201611
Approvedterm2
1 yr 0 mth
Pinamesdelim
Franco, Eduardo L
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $26,186~ $0~